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ABSTRACT: The liver is the primary organ involved in
handling of bile salts, a class of amphipathic molecules with
signaling activities as well as desired and detrimental detergent
actions. To allow in-depth investigation of functions of bile
salts in healthy and diseased liver, the spatial distribution of
bile salt species within the liver needs to be studied.
Therefore, the aim of our study was to determine hepatic
bile salt distribution and identify speciﬁc lipid markers that
deﬁne the structural elements of the liver. Matrix-assisted laser
desorption/ionization-mass spectrometry imaging (MALDI-
MSI) was used to monitor the spatial distribution of bile salts
and lipids in liver sections of rat, dog, and patients with
unaﬀected and cholestatic parenchyma. MALDI-MSI in
negative ion mode showed the local presence of a variety of bile salts, predominantly taurine-conjugates, as localized patches
of varying sizes (representing the bile ducts) throughout the liver tissue. Speciﬁc molecular markers were identiﬁed for the
connective tissue (phosphatidic acids, e.g., [PA (18:0_18:1)−H]−), the liver parenchyma (phosphatidylinositols, e.g., [PI
(18:0_20:4)-H]−), and the bile ducts (hydroxylated-sulfatides, e.g., [ST−OH (18:1_24:0)-H]−). One of these sulfatides (at m/
z 906.6339) was found to be uniquely localized in a thin lining on the inside of the bile duct, colocalized with cytokeratins, and
encased luminal bile salts. A similar distribution of the aforementioned sulfatide was observed, albeit in constricted ductular
structures, in the liver of a patient with a mild clinical phenotype of primary sclerosing cholangitis (PSC). In contrast, sulfatides
were virtually absent in the liver of patients with PSC and a severe clinical phenotype, with (atypical) cholanoids (e.g., the bile
alcohol 5-cyprinolsulfate) abundant in the extra-ductular space and glyco(cheno)deoxycholic acid-3-sulfate localized to ﬁbrotic
connective tissue. The latter two molecular species were able to discriminate between healthy liver tissue (n = 3) and tissue
from PSC patients with a severe clinical phenotype (n = 3). In conclusion, the distinct structural elements of the mammalian
liver are characterized by speciﬁc classes of lipids. We propose that (hydroxylated-)sulfatides are speciﬁc molecular markers of
the bile duct.
During the past two decades, bile salts have been upgradedfrom molecules required for absorption of dietary lipids
and fat-soluble vitamins, to signaling molecules regulating
biological processes as diverse as nutrient metabolism,
inﬂammation, and liver regeneration.1−4 The discovery of
bile salt receptors that mediate these signaling activities was
key to the renewed interest in bile salts by academic and
pharmaceutical communities. In particular, Farnesoid-X
Receptor (FXR), a bile salt-activated transcription factor with
an essential role in bile salt homeostasis, has been studied
extensively. FXR agonism-based therapy has already been
approved for treatment of patients with primary biliary
cholangitis (PBC) and inadequate response to ursodeoxycholic
acid.5 Multiple clinical trials are ongoing to evaluate eﬃcacy of
FXR agonists in treatment of metabolic liver disorders like
nonalcoholic steatohepatitis (NASH).6,7
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The liver is the primary organ involved in the synthesis and
handling of bile salts. Being amphipathic molecules, bile salts in
the aqueous phase can interact with biological membranes.
Consequently, the liver is the prime site where injury occurs
when bile formation or ﬂow of bile is impaired, and toxic levels
of bile salts build up inside the parenchymal cells. At a certain
threshold, intracellular bile salts damage mitochondrial
membranes and initiate a sterile inﬂammatory response that
results in immune-mediated tissue injury.8−10 In drug develop-
ment, drug-induced cholestasis is a common reason for halting
further development in preclinical phases of testing.11
Distinct bile salt species arise from diﬀerent synthetic routes
in the host, utilization of either glycine or taurine for formation
of N-amidated conjugates, and biotransformation by the gut
microbiota.1 Individual bile salt species have distinct signaling
properties and toxicity proﬁles. Mass spectrometry (MS)-based
analytical tools have been of great value to determine bile salt
composition of (homogenized) biospecimens (e.g., serum, bile,
urine, feces, and liver tissue) from healthy and diseased
subjects.
Study of hepatic bile salt composition requires the
preparation of a homogenate, inevitably resulting in loss of
spatial information. As several aspects of hepatic bile salt
handling are known to be zonated (e.g., extraction of bile salts
from the portal supply in the periportal area, de novo synthesis
in the pericentral area),12 information on the local distribution
of bile salts within the liver could further advance our
understanding of bile salt (patho)physiology.
Matrix-assisted laser desorption/ionization-mass spectrome-
try imaging (MALDI-MSI) has been extensively used to
monitor the distribution of drugs, lipids, peptides, and proteins
in tissue sections, making this an ideal tool to determine the
molecular proﬁles of the various compartments of healthy and
diseased liver. Here we used MALDI-MSI to study the spatial
distribution of bile salts within the liver of animal species
commonly used in preclinical drug testing, as well as in
noncholestatic and cholestatic human liver parenchyma.
Speciﬁc aims were (i) to determine whether it is feasible to
determine the spatial distribution of distinct bile salt species in
the liver, including those with identical molecular mass, (ii) to
identify lipid molecular markers that deﬁne the structural
elements of the liver anatomy, and (iii) determine if there are
unique molecular proﬁles that can distinguish between healthy
and diseased human liver and compare with those obtained
from preclinical animal species. This spatial molecular
information can be employed to address roles of deﬁned
molecules in liver (dys)function, both in the context of human
pathology and drug screening programs.
■ METHODS
Materials. Cholic acid (CA), deoxycholic acid (DCA),
chenodeoxycholic acid (CDCA), lithocholic acid (LCA),
taurocholic acid (TCA), taurodeoxycholic acid (TDCA),
taurochenodeoxycholic acid (TCDCA), glycocholic acid
(GCA), glycochenodeoxycholic acid (GCDCA), glycodeox-
ycholic acid (GDCA), 2,5-dihydroxybenzoic acid (DHB), 9-
aminoacridine (9AA), chloroform (CHCl3), and triﬂuoroacetic
acid (TFA) were purchased from Sigma-Aldrich (Zwijndrecht,
The Netherlands). Methanol (MeOH) was purchased from
Biosolve (Valkenswaard, The Netherlands).
Liver Specimens. A healthy canine liver specimen
(Marshall Beagle, n = 1) was obtained in the framework of
an ongoing study at Janssen Pharmaceutica N. V. The study
was approved by the local animal ethical committee and
conducted in facilities accredited by national institutions
adhering to AAALAC guidelines. Human liver specimens
were obtained from patients undergoing either resection for
hepatobiliary malignancies (nonaﬀected liver tissue sample
distant from the tumor, n = 3) or undergoing liver
transplantation for end-stage liver disease (PSC, n = 6).
Patients with PSC were classiﬁed as severe cases if bilirubin
was ≥34 μmol/L along with ≥2 abnormal liver tests, which
included aspartate aminotransferase (AST), alanine amino-
transferase (ALT), alkaline phosphatase (ALP), gamma-
glutamyl transferase (GGT), and international normalized
ratio (INR) (see Table S1). Specimens were procured as part
of biobank initiatives at the Aachen (Medical Ethical approval
no. EK 20609) and Maastricht (Medical Ethical approval no.
14-4-153) locations of the Euregional Surgical Center Aachen
Maastricht (ESCAM) or from the Erasmus MC, Rotterdam
(Medical Ethical approval no. 167.902/1998/33 and no. 2014-
060). Patients gave written informed consent for biobanking
and research use of surgical specimens. A rat liver specimen
(Wistar Han, n = 1) was obtained from a control group of rats
sacriﬁced for a study on colonic anastomotic healing (approved
by the local Animal Ethics Committee of the Radboud
University, Nijmegen). Per liver specimen, multiple sections
throughout the tissue were analyzed [i.e., dog (n = 7),
noncholestatic patient (n = 7), PSC patients (n = 4), and rat (n
= 9)].
Tissue Preparation. Liver tissue was sectioned using a
Microm HM535 cryo-microtome (Microm International,
Walldorf, Germany) at a temperature of −20 °C to produce
10 μm thick sections, which were thaw-mounted onto clean
indium tin oxide (ITO)-coated glass slides (4−8 Ω resistance,
Delta Technologies, Stillwater, MN, USA). Tissue sections
were scanned prior to matrix application using a Nikon Super
CoolScan 5000 ED (Nikon Corporation, Tokyo, Japan) to
produce high-quality optical images. Consecutive tissue
sections were thaw-mounted on regular glass slides (Thermo
Scientiﬁc) for histological and immunohistochemical staining.
Matrix Application. Tissue sections were coated with 15
mg/mL DHB in 2:1 CHCl3:MeOH with 0.2% TFA using the
SunCollect automated pneumatic sprayer equipped with
dispenser system (Sunchrom GmbH, Friedrichsdorf, Ger-
many) in a series of 15 layers. The initial seeding layer was
performed at 10 μL/min; subsequent layers were performed at
20, 30, and 40 μL/min, respectively (all at speed 450 mm/min,
track spacing: 2 mm, height: 23 mm). For negative-ion mode
some tissue sections were coated with 10 mg/mL 9AA in
70:30 MeOH:H2O in a series of 10 layers. The initial seeding
layer was performed at 10 μL/min; subsequent layers were
performed at 15, 20, and 25 μL/min, respectively (all at speed,
450 mm/min; track spacing, 2 mm; height, 25 mm).
Instrumentation. MALDI-MSI. High-speed imaging was
performed on a Bruker RapiﬂeX MALDI Tissuetyper system
(Bruker Daltonik GmbH, Bremen, Germany) equipped with a
neodymium-doped yttrium aluminum garnet (Nd:YAG) laser
(355 nm, 10 kHz); a more detailed description of this
instrument is provided elsewhere.13 The instrument was
operated in reﬂectron mode in both positive- and negative-
ion modes in the mass range m/z 400−1000. The instrument
was calibrated prior to analysis using red phosphorus clusters
in both polarities. The laser power was 80% with an
accumulation of 200 shots. Images of the whole tissue sections
were acquired using a 50 × 50 μm raster (25 × 25 μm beam
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scan area). The images were generated using the FlexImaging
version 5.0 software (Bruker Daltonik GmbH) and were
normalized to the total ion current (TIC).
MALDI-FTICR-MSI. For conﬁrmation of molecular identity,
high-mass resolution (100,000 at m/z 500) measurements
were performed on a Bruker SolariX FTICR mass
spectrometer (Bruker Daltonik GmbH, Bremen, Germany)
equipped with a 9.4 T superconducting magnet and Nd:YAG
laser. The instrument was operated in both positive- and
negative-ion modes in the mass range m/z 100−2000. The
instrument was calibrated prior to analysis using red
phosphorus clusters in both polarities. The laser power was
30% (2 kHz) with an accumulation of 100 shots. Images were
acquired with a pixel size of 15 μm. A 95% data reduced proﬁle
spectrum and spectrum peak list were saved for further
analysis. The images were generated using the FlexImaging
version 4.1 software (Bruker Daltonik GmbH) and were
normalized to the total ion current (TIC).
MALDI-MS/MS. For further conﬁrmation of molecular
identity, a Waters MALDI HDMS Synapt G2-Si mass
spectrometer (Waters Corporation, Manchester, UK) equip-
ped with an Nd:YAG laser was used to perform ion mobility
separation (IMS) and tandem mass spectrometry (MS/MS)
measurements. The instrument was calibrated using red
phosphorus prior to analysis. MS/MS was performed on
consecutive tissue sections, the laser power was 150 arbitrary
units (1 kHz), and the ions of interest were fragmented by
collision induced dissociation (CID) in the trap cell with an
isolation window of approximately 3 Da. For ion mobility, the
IMS wave velocity was 900 m/s and the wave height was 40 V.
For presentation purposes, mass spectra from the MassLynx
version 4.1 software (Waters Corporation) were exported in
the form of text ﬁles and imported into mMass, open-source
software used for mass spectral processing.14 The MS/MS
spectra from the commercial bile acid standards and tissue
sections were compared to those in the literature or databases
such as lipid maps (www.lipidmaps.org) and the ALEX123
lipid calculator (www.alex123.info). The fragment ions
observed in each MS/MS spectrum were assigned based on
the recently proposed nomenclature for lipids.15
TOF-SIMS. High spatial resolution imaging was performed
using a PHI nanoTOF II TOF-SIMS instrument (Physical
Electronics, Minnesota, MN, USA) equipped with a 30 kV
Bin
q+ cluster liquid metal ion gun (LMIG), which was operated
with a Bi3+ cluster ion beam. Images were acquired using a tile
size of 500 × 500 μm at 30 frames with an ion dose of 2.59 ×
1012 ions/cm2 in negative ion mode; the data was acquired in
the mass range m/z 0−1850 and a spatial resolution of ∼1 μm.
The instrument was calibrated using a combination of
elements and hydrocarbon fragments. The images were
generated using software PHI TOF-DR software (Physical
Electronics).16
Tissue Staining. Hematoxylin and eosin (H&E) and
Masson’s trichrome (MTC) staining was performed on
consecutive tissue sections (10 μm) followed by aqueous
mounting. Optical images of all stained tissue sections were
acquired using a Mirax desk scanner (Zeiss, Gottingen,
Germany). Cryosections (5 μm thickness) of liver tissue
were used for immunohistochemistry; thinner tissue sections
were required to reduce background signal. The bile duct
epithelium was stained using a wide spectrum anticytokeratin
antibody (Dako/Agilent Pathology Solutions) and secondary
detection reagents. Detailed protocols are located in the
Supporting Information.
Statistical Analysis. Statistical analyses were performed on
the MALDI-FTICR-MSI data using the in-house built
ChemomeTricks toolbox for Matlab version 7.0 software
(The MathWorks, Natick, MA, USA).17 Brieﬂy, peak picking
was performed on an average spectrum (created using the
peaks sqlite ﬁle) at a 0.001 Da bin size. The center of the peaks
and integration ranges were deﬁned, to account for peak
shifting from pixel-to-pixel. Principal component analysis
(PCA) was then performed on the converted data sets,
which were normalized to the total ion current. The peak list
from each principal component that highlighted diﬀerent areas
of the liver was exported, and the top ten peaks (based on
intensity) were then identiﬁed.
Further statistical analysis was performed on the MALDI-
FTICR-MS imaging data set from healthy human liver (n = 3)
and liver from patients with severe PSC (n = 3), using SCiLS
lab version 2016b (SCiLS GmbH, Bremen, Germany). The
results were normalized to the total ion current (TIC), and an
average spectrum was created from all samples which was
imported into the mMass software and subjected to peak
picking, to create a peak list which was imported back into
SCiLS lab. A receiver operating characteristic (ROC) analysis
was performed to determine the power of selected molecular
species to discriminate between healthy liver and cases of
severe PSC.
■ RESULTS AND DISCUSSION
Identiﬁcation of Bile Salts. In order to have optimal
sensitivity and selectivity of the method applied, the
physiologically most relevant (non)conjugated primary and
secondary bile salts (Figure S1) were spotted individually on a
target plate, coated with 9AA, and analyzed with MALDI-MS,
according to previous works.18,19 All bile salts were observed in
their deprotonated form ([M − H]−). MS/MS experiments
were performed on the standards (Figure S2). The taurine-
conjugated bile salts showed characteristic product ions,
indicating the fragmentation or loss of taurine such as m/z
80 (SO3
−), 107 (C2H3O3S
−), and 124 (C2H6NO3S
−), whereas
the glycine-conjugated bile salts showed the loss of glycine m/z
74 (C2H5NO2
−).20,21 The unconjugated bile salts showed
fragments resulting from the loss of H2O, CO2, and CH2O2.
21
Isomeric species, such as chenodeoxycholic acid (CDCA),
deoxycholic acid (DCA), and their conjugated forms, can be
separated using chromatographic techniques.22 Here, ion
mobility separation (IMS) was evaluated for separation of
isomeric bile salts. Standards of the isomeric bile salts were
applied as a mixture on a target plate and analyzed. Using this
technique, it was possible to diﬀerentiate between DCA and
CDCA (Figure S3A); however, it was not possible to separate
the taurine (Figure S3B) or glycine-conjugated variants thereof
(Figure S3C). This is likely due to the limited resolution of
current commercial ion mobility instrumentation. Since the
bulk of hepatic bile salts are conjugated, IMS was not suitable
to analyze isomeric bile salt species in intact tissues.
Spatial Distribution of Bile Salts and Lipids in
Healthy Dog Liver. High-speed imaging experiments on
whole liver tissue sections (at a spatial resolution of 50 μm)
showed the distinct distribution of various molecular markers
linked to the diﬀerent tissue types found in the liver. Regions
such as the parenchyma, the bile ducts, the connective tissue,
and the bile duct lumen could be clearly distinguished in these
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MALDI-MS images (Figure 1A and S4A). Following analysis
of the whole tissue section, high mass and high spatial
resolution MALDI-FTICR-MSI was performed on speciﬁc
areas, selected based on histological and molecular features
(Figure 1B and S4B). These images provided greater spatial
detail of the selected molecular species and improved mass
accuracy, improving molecular identiﬁcation.
The optical image of the whole liver tissue section prior to
analysis (Figure 1, panels A and B, I) shows a homogeneous
parenchyma with a cluster of large blood vessels in the center
of the tissue. Histological staining of consecutive tissue
sections was performed for reference. The hematoxylin and
eosin stain (Figure 1, panels A and B, II) diﬀerentiates the
eosinophilic hepatocellular parenchyma from the brighter
(slightly eosinophilic) stained portal areas, whereas the blue
Masson’s trichrome stain (Figure 1, panels A and B, III)
highlights the presence of collagen, indicating the portal
connective tissue. This is abundant around the large blood
vessels, with smaller patches located throughout the tissue
section.
MALDI-MS imaging in negative-ion mode showed the
presence of predominantly taurine-conjugated bile salts, the
most abundant were taurocholic acid (TCA) and taurocheno-
deoxycholic/taurodeoxycholic acid (TCDCA/TDCA). This is
to be expected as dogs use primarily taurine for bile acid
conjugation.23,24 The distribution of TCA at m/z 514.28
(Figure 1A, IV) showed localized patches of varying sizes
throughout the tissue, most likely representing the bile ducts.
The larger ones (average diameter 175−250 μm), which are in
close proximity to the large blood vessels, are septal bile ducts.
Smaller bile ducts (average diameter 20−70 μm) distributed
throughout the tissue, are the interlobular bile ducts.25 The
identity of TCA was conﬁrmed by MS/MS measurements
(Figure S5A). Interestingly, 3-keto-TCA and 3-keto-TDCA/
TCDCA were also present in the bile duct lumen. Keto bile
salts were previously detected in bear bile.26 Next to this,
taurolithocholic acid was also present. The connective tissue
showed a strong presence of a lipid at m/z 701.51 (Figure 1A,
V), which was identiﬁed by MS/MS measurements as a
phosphatidic acid [PA (18:0_18:1) − H]− (Figure S5B). This
species was distributed throughout the tissue but appeared to
be more abundant in the connective tissue, which correlates
well with Masson’s trichrome staining (Figure 1, panels A and
B, III). The connective tissue was also characterized by other
phosphatidic acids, phosphatidylserines (PS), and sphingo-
myelin (SM) fragments ([M − CH3]−).27 It should be noted
that the positive ion counterparts of the SM fragments
colocalized with observed species, hence conﬁrming their
Figure 1. Multimodal imaging of healthy dog liver tissue. (I) Optical image of the tissue section prior to matrix application or staining. (II) Tissue
sections stained with hematoxylin and eosin stain, and (III) Masson’s trichrome. Negative-ion mode (A) MALDI-MS and (B) MALDI-FTICR-MS
images showing the distribution of selected molecular species in the (IV) bile duct lumen ([TCA − H]− at m/z 514.2849); (V) connective tissue
([PA (18:0_18:1) − H]− at m/z 701.5129); (VI) parenchyma ([PI (18:0_20:4) − H]− at m/z 885.5504); (VII) bile duct ([ST−OH (18:1_24:0)
− H]− at m/z 906.6339); and (VIII) overlay of the selected species. (Designated masses are from MALDI-FTICR-MS imaging measurements,
MALDI-MS image ﬁeld of view 140785 pixels, area 124 mm2, and spatial resolution 50 μm. MALDI-FTICR-MS image ﬁeld of view 51761 pixels,
11.6 mm2 area, and spatial resolution 15 μm. Images normalized with TIC).
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identiﬁcation (see Figure S4). In the surrounding liver
parenchyma, the most abundant species, which was homoge-
neously distributed throughout the parenchyma but absent
from the other areas of the tissue was identiﬁed using MS/MS
measurements as a phosphatidylinositol (PI), speciﬁcally [PI
(18:0_20:4) − H]− at m/z 885.55 (Figure 1A, VI and Figure
S5C). Other PIs, PAs, and phosphatidylethanolamines (PE)
were predominantly present in this area.
Another lipid species at m/z 906.64 (Figure 1A, VII) was
distributed in small localized patches throughout the tissue and
colocalized with the distribution of bile salts. The overlay of
the selected species (Figure 1A, VIII) shows that selected
species colocalize well together and clearly highlight the
diﬀerent boundaries of the molecular components that make
up the bile duct and surrounding tissue. Following analysis of
the whole tissue section, high mass and high spatial resolution
MALDI-FTICR-MS imaging was performed on selected areas,
which was selected based on histological and molecular
features. This provided far more detail of the selected
molecular species, as well as improved mass accuracy enabling
better conﬁrmation of their identity (Figure 1B, III−V).
Interestingly, MALDI-FTICR-MS analysis revealed that the
species at m/z 906.6339 was localized in a thin lining on the
inside of the bile duct (Figure 1B, VII). This compound was
identiﬁed, by MS/MS measurements, as a hydroxylated-
sulfatide [ST−OH (18:1_24:0) − H]− (Figure S5D), a
ceramide derivative previously identiﬁed by MALDI-MS/MS
imaging of brain tissue.28 Nonhydroxylated sulfatides (ST)
were also present in the bile duct. The overlay of the selected
molecular species (Figure 1B, VIII) recapitulated the general
histological features of the liver. All peaks identiﬁed in the
diﬀerent regions of the healthy dog liver are shown in Tables
S2 and S3.
Spatial Distribution of Bile Salts and Lipids in
Healthy Human Liver. Healthy human liver tissue was
analyzed next to study (dis)similarities in spatial distribution of
Figure 2. Multimodal imaging of healthy human liver tissue. (I) Optical image of tissue section prior to matrix application or staining. (II) Tissue
sections stained with hematoxylin and eosin and (III) Masson’s trichrome stain. Negative-ion mode (A) MALDI-MS and (B) MALDI-FTICR-MS
images showing the distribution of selected molecular species in the (IV) bile duct lumen ([TCA − H]− at m/z 514.2849); (V) connective tissue
([PA (18:0_18:1) − H]− at m/z 701.5128); (VI) parenchyma ([PI (18:0_20:4) − H]− at m/z 885.5504); and (VII) bile duct ([ST−OH
(18:1_24:0) − H]− at m/z 906.6339). (VIII) Overlay of the selected species. (Designated masses are from MALDI-FTICR-MS imaging
measurements, MALDI-MS image ﬁeld of view 78624 pixels, area 110 mm2, and spatial resolution 50 μm. MALDI-FTICR-MS image ﬁeld of view
24915 pixels, 5.5 mm2 area, and spatial resolution 15 μm. Images normalized with TIC).
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bile salt species and molecular lipid markers of structural
elements in the human liver (Figure 2 and S6). Optical and
histological images were again acquired for reference (Figure 2,
panels A and B, I−III). MALDI-MSI showed high signal
intensities of TCA at m/z 514.28 and TCDCA/TDCA at m/z
498.28, whereas lower signal intensities of glyco(cheno)-
deoxycholic acid (GCDCA/GDCA) at m/z 448.30 and
glycocholic acid (GCA) at m/z 464.30 were present (Table
S3). These ﬁndings were somewhat unexpected since the
human bile salt pool consists largely of glycine-conjugated
species, with taurine-conjugated bile salts comprising approx-
imately 20% of the biliary bile salt pool.24 This discrepancy is
most likely attributed to the fact that the sulfonate group of
taurine conjugates is more easily ionized in negative-ion mode
than the carboxylic acid group of glycine conjugates.18,19 The
distribution of TCA at m/z 514.28 (Figure 2A, IV) showed a
few small localized patches throughout the tissue, indicating
the presence of bile ducts. Both septal and interlobular bile
ducts were apparent in the studied specimen. Taurine-
conjugated keto bile salts and lithocholate were also detected
in the bile ducts. Also in human liver tissue, the connective
tissue was deﬁned by [PA (18:0_18:1) − H]− at m/z 701.51
(Figure 2A, V), and distribution of this lipid species matched
the Masson’s trichrome staining (Figure 2, panels A and B,
III). Connective tissue was also characterized by SM fragments
and PS. Human liver parenchyma (Figure 2A, VI) was
characterized by a PI [PI (18:0_20:4) − H]− at m/z 885.55, as
well as other PIs, PAs, and PEs. The hydroxylated-sulfatide
[ST−OH (18:1_24:0) − H]− at m/z 906.63 (Figure 2A, VII)
appeared as small localized patches throughout the tissue. The
overlay of the selected species (Figure 2A, VIII) shows how the
selected ions colocalize and indicated the best area for high
spatial resolution MALDI-FTICR-MS imaging. The images
again only showed detailed views of the other selected species
(Figures 2B, IV−VI). MALDI-FTICR-MSI analysis showed
the hydroxylated-sulfatide [ST−OH (18:1_24:0) − H]− at m/
z 906.6340 as a thin band located in the bile duct (Figure 2B,
VII). The overlay of the selected species (Figure 2B, VIII)
demonstrated the localization of the bile salts within the bile
duct lumen, which was bordered by a lining of the
aforementioned hydroxylated-sulfatide. Additional hydroxy-
lated and nonhydroxylated sulfatide species were observed in
the bile duct wall. The peaks identiﬁed in the diﬀerent regions
of the healthy human liver are shown in Tables S2 and S3.
Sulfatides are Novel Molecular Markers for the Bile
Duct Epithelium. Hydroxylated-sulfatide [ST−OH
(18:1_24:0) − H]− was identiﬁed in both healthy dog and
human liver tissue and speciﬁcally localized as a thin band
lining the bile duct. This compound was the most prominent
of several hydroxylated and nonhydroxylated sulfatides that
colocalized in the bile duct (Table S3). In order to determine
whether sulfatides are speciﬁc markers for the bile duct,
immunohistochemical staining for cytokeratins was performed
on sections of dog and human liver (Figure 3). This revealed
the presence of cytokeratins in the cholangiocytes/bile duct
epithelium (Figure 3, panels A and B, II). MALDI-MSI of a
consecutive section revealed [ST−OH (18:1_24:0) − H]− at
m/z 906.63 distributed as a ring-like structure (Figure 3, panels
A and B, III). High spatial resolution TOF-SIMS imaging of
consecutive sections of dog and human liver conﬁrmed the
conﬁnement of sulfatides to the bile duct epithelium (Figure 3,
panels A and B, IV). The molecular images correlate well with
the immunohistochemical staining of the bile ducts indicating
that these species, as well as the other sulfatide species (Table
S3) are molecular markers for the bile duct epithelium.
The unique localization of sulfatides to bile duct epithelium
suggests a biologically relevant role. Sulfatides are glyco-
sphingolipids that contain an extra sulfate group and hence are
commonly observed in negative-ion mode. Sulfatides are
predominantly found in the exoleaﬂet of the membrane bilayer
and have been detected in diﬀerent tissues, including the brain
where they are an abundant component of the myelin sheath,
the pancreas (the islets of Langerhans), and the kidney.29
Figure 3. Comparison of immunohistochemical staining, MALDI-MS
imaging and TOF-SIMS imaging of (A) healthy human and (B) dog
liver. (I) Hematoxylin and eosin stain of tissue section post-MALDI-
MSI analysis. (II) Cytokeratin staining shows the bile duct epithelium.
Negative-ion mode (III) MALDI-MS imaging and (IV) TOF-SIMS
imaging of the bile ducts showing the distribution of [ST−OH
(18:1_24:0) − H]− at m/z 906.63. (MALDI-MS image (dog) ﬁeld of
view 15875 pixels, area 1.60 mm2, and spatial resolution 10 μm.
MALDI-MS image (human) ﬁeld of view 30420 pixels, area 3.05
mm2, and spatial resolution 10 μm. TOF-SIMS (dog/human) ﬁeld of
view 250000 pixels, area 0.25 mm2, and spatial resolution 1 μm.
Images normalized with TIC).
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Although sulfatides were previously detected in liver, their
presence could not be attributed to a particular region because
those studies were performed on tissue extracts.30 Sulfatides
are negatively charged and will likely repel negatively charged
Figure 4. Multimodal imaging of human liver from patients with (A) mild PSC and (B) severe PSC. (I) Optical image of tissue section prior to
matrix application or staining. Consecutive tissue sections stained with (II) hematoxylin and eosin (III) Masson’s trichrome. Negative-ion mode
MALDI-FTICR-MS images showing the distribution of (IV) [TCA − H]− at m/z 514.2855; (V) sulfated bile alcohol ([M − H]−) at m/z
531.2999; (VI) bilirubin diglucuronide ([M − H]−) at m/z 935.3218; (VII) heme ([M − H]−) at m/z 615.1704; (VIII) [PA (18:0_18:1) − H]−
at m/z 701.5128; (IX) [PI (18:0_20:4) − H]− at m/z 885.5504; and (X) [ST−OH (18:1_24:0) − H]− at m/z 906.6353. (XI) Overlay of the
selected species. (Mild PSC image ﬁeld of view 20326 pixels and area 10 mm2, severe PSC image ﬁeld of view 63744 pixels, and area 14 mm2.
Spatial resolution of both images 15 μm, normalized with TIC).
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compounds, such as bile salts, and may accordingly play a role
in protecting the bile duct epithelium from detergent action of
bile salt anions. Information on speciﬁc roles of sulfatides in
liver biology is sparse. Sulfatides are self-lipid antigens, and
presence of autoantibodies appears to be common in chronic
autoimmune liver diseases like autoimmune hepatitis and
primary biliary cholangitis (PBC).31 Sulfatides presented by
CD1d protein are recognized by type 2 natural killer T (NKT)
cells. In the liver, NKT cells are abundant in the sinusoids, with
type I and type II NKT cells having a pro- and anti-
inﬂammatory action, respectively.32 Immune-mediated liver
injury in an animal model of alcoholic liver disease is
dependent on type I NKT cells.33 Interestingly, activation of
type II NKT cells by sulfatides prevented inﬂammation and
liver disease in this model and may have a broader role in a
tolerogenic response in inﬂammatory liver disease.34 Given the
abundance of this lipid in the bile ducts, a link with
inﬂammatory cholangiopathies like PBC and primary scleros-
ing cholangitis (PSC) is plausible.
Spatial Distribution of Bile Salts and Sulfatides in
Liver of PSC Patients. Liver tissue from six patients
undergoing liver transplantation for treatment of PSC was
analyzed by MALDI-FTICR-MSI (Figures 4 and S7) to
explore whether molecular species are globally similar in
diseased liver tissue. The ﬁrst PSC patient (case 1, Table S1)
was noncholestatic and was considered to have a mild clinical
phenotype. Histological evaluation of a liver biopsy taken prior
to transplantation revealed mild inﬂammation but no ﬁbrosis.
Severe cases of PSC (n = 3) were characterized by cholestasis
(bilirubin ≥ 34 μmol/L) and cholestatic liver injury/
dysfunction (≥2 liver test abnormalities) (Table S1).
Mild PSC. The optical image of the tissue section showed
an elongated cluster of bile ducts/blood vessels surrounded by
connective tissue and a homogeneous parenchyma (Figure 4A,
I). Hematoxylin and eosin (Figure 4A, II) and Masson’s
trichrome staining of liver sections of the initial patient with
mild PSC (Figure 4A, III) revealed concentric periductal
ﬁbrosis with little periductal inﬂammatory inﬁltrate. In
addition, mixed inﬂammatory cells and bile ductular
proliferation were found at the periphery of the portal area
extending into the interlobular septa. For both patients (cases
1 and 2), the histological features observed in the hepatic
parenchyma, bile ducts, and portal areas are associated with
PSC.35 Despite these morphological diﬀerences, liver tissue of
the patient with mild PSC showed the same distribution of
selected molecular species as healthy human liver tissue.
Taurine-conjugated species were the most abundant bile salt
species and localized to the bile duct lumen (Figure 4A, IV).
Blood vessels in the portal area were marked by the presence of
heme (Figure 4A, VII). Molecular markers identiﬁed in the
healthy human liver also deﬁned the connective tissue (Figure
4A, VIII), parenchyma (Figure 4A, IX), and the bile ducts in
the patient with mild PSC. The distribution of [ST−OH
(18:1_24:0) − H]− at m/z 906.6353 (Figure 4A, X) indicated
that the bile ducts were narrowed, a hallmark histological
feature observed in PSC.37 The overlay shows that the selected
species colocalize well together and clearly highlight the
diﬀerent boundaries of the molecular components (Figure 4A,
XI). The mild/severe PSC (case 4) is classed as such due to
elevated bilirubin and clotting function, the liver also has
slightly above normal aspartate aminotransferase levels (>40
U/L). All other parameters within the normal range (Table
S1).
Severe PSC. The optical image shows an inhomogeneous
parenchyma with ﬁbrotic connective tissue dispersed through-
out the tissue (Figure 4B, I). Histological examination of the
liver from the initial patient with severe PSC (case 2, Figure
4B, II and III) showed a diminished number/absence of
interlobular bile ducts, portal-to-portal bridging ﬁbrosis, bile
ductular proliferation in portal areas, and ﬁbrous septa with
minimal mononuclear inﬂammatory inﬁltrate. In addition
nodular hepatocellular regeneration, ballooning degeneration
of hepatocytes, and yellow to brown pigmentation were noted.
Taurine-conjugated species were also present in the liver of the
patient with severe PSC (Figure 4B, IV); however, they appear
to have diﬀused out of the bile ducts into the surrounding
parenchyma. This is reminiscent of regurgitation of bile salts
from leaky bile ducts into the portal tracts in an animal model
of PSC.36 Moreover, a unique bile salt species at m/z 531.2999
was observed (Figure 4B, V). MS/MS measurements indicated
loss of m/z 97 (HSO4
−) and m/z 80 (SO3
−), leading to its
tentative identiﬁcation as 5-cyprinolsulfate (5-CS). To our
knowledge, the presence of 5-CS (a sulfated bile alcohol
abundant in cypriniform ﬁshes)37 has not been previously
reported in humans and likely relates to cholestasis where
elevation of urinary bile alcohols was previously observed.38 In
order to conﬁrm molecular identity, a whole-body tissue
section of a zebra ﬁsh, an authentic source of 5-CS, was
analyzed. The MALDI-MS/MS spectrum of 5-CS obtained
from the initial patient with severe PSC was comparable to that
obtained from the zebra ﬁsh (Figure S8A). Glyco(cheno)-
deoxycholic acid-3-sulfate (G(C)DCA-S) at m/z 528.2639 was
also identiﬁed in the liver of the initial patient with severe PSC,
which was not detected in the mild PSC case. The MALDI-
MS/MS spectrum of an authentic standard is shown in Figure
S8B. Molecular identity of G(C)DCA-S in liver tissue was
further supported by MALDI-FTICR-MS and MS/MS
measurements. In general, sulfation of bile salts is an adaptive
mechanism to promote elimination of bile salts that have
accumulated in the liver.39
Furthermore, both unconjugated and conjugated bilirubin
was observed. The MALDI-FTICR-MS images show that the
distribution of bilirubin at m/z 583.2569, bilirubin mono-
glucuronide at m/z 759.2899, and bilirubin diglucuronide at
m/z 935.3218 (Figure 4B, VI) coincided with that of bile salts.
Of note, 5-CS and bilirubin (conjugated and unconjugated)
were not detected in the liver from the patient with mild PSC
(Figures 4A, V and VI, respectively) whose serum bilirubin
levels were within the normal range. Elevation of bilirubin can
be seen following obstruction of bile ﬂow resulting in the
release of conjugated bilirubin into the bloodstream. The lipid
at m/z 701.5128, identiﬁed as [PA (18:0_18:1) − H]−, was
abundant in the connective tissue surrounding the blood
vessels (Figure 4B, VII) and bile ducts, with a notably thicker
layer when compared to liver of the patient with mild PSC
(Figure 4A, VIII) and is dispersed throughout the parenchyma
(Figure 4B, IX) which is apparent from the overlay of the
selected species (Figure 4B, XI). Despite the occurrence of
discrete patches of biliary constituents (i.e., bile salts and
bilirubin glucuronides) that indicates that bile ducts are
present (as conﬁrmed by staining of consecutive sections for
cytokeratins), hydroxylated and nonhydroxylated sulfatides
were virtually absent in the liver of the initial patient with
severe PSC (Figure 4B, X and Figure S9). It is currently
undetermined if absence/disappearance of sulfatides from the
bile ducts has pathological relevance. The presence of
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sulfatides in tissue of severe PSC cases (Figure 4B, X) could be
attributed to small bile ducts that are typically not aﬀected in
PSC.35 In contrast, the larger bile ducts appeared to be
generally devoid of sulfatides and may have been damaged, as
bile salts were found in abundance into the surrounding
parenchyma. Thus, bile salts do not colocalize with the
sulfatides that are still present in severe PSC.
To determine the generality of the above ﬁndings, liver
samples from four additional patients with PSC were analyzed
and conﬁrmed the presence and localization of 5-CS and
G(C)DCA-S in each sample, albeit in varying abundance
(Figure S10). To determine whether the observed molecular
species can diﬀerentiate between healthy human liver tissue
and severe PSC liver tissue, ROC analysis was performed. For
this, three healthy liver specimens were compared to the three
cases of severe PSC where cholestatic liver injury was evident
(cases 2, 5, and 6). Liver from the three cases of mild PSC (1,
3, and 4) was also compared with healthy liver, revealing that
ROC values for 5-CS, G(C)DCA-S, and the other character-
istic ions were approximately 0.5. Thus, it was not possible to
diﬀerentiate between healthy tissue and cases of mild PSC
(data not shown).
G(C)DCA-S at m/z 528.2633 (AUC 0.957) and 5-CS at m/
z 531.3000 (AUC 0.835) clearly diﬀerentiated between healthy
liver tissue and severe PSC liver tissue (Figure S11). The
atypical shape of the 5-CS ROC plot is due to the peak picking
threshold, and the fact that a lot of pixels in the image have an
intensity of zero. This is also apparent from the MALDI-
FTICR-MS images of 5-CS (Figure S10), which is observed as
small localized patches. In contrast, G(C)DCA-S is distributed
throughout the tissue, hence the ROC plot has a later plateau
due to the high number of pixels. 5-CS and G(C)DCA-S
displayed diﬀerent spatial distributions in severe PSC (Figure
S10, panels F and G), with 5-CS colocalizing with TCA and
both seeming to spread into the parenchyma. In contrast,
G(C)DCA-S appeared to localize to connective tissue. The
mechanistic base for these distinct distributions is unclear. The
other examined molecular species (e.g., TCA, T(C)DCA and
bilirubin) did not have as much discriminating power (AUC
0.626, 0.721, and 0.568, respectively, Table S4). The molecular
species identiﬁed in the liver of both mild and severe cases of
PSC samples are shown in Tables S2 and 3.
Interspecies Comparison of Molecular Proﬁles of
Healthy Livers. Healthy rat liver was analyzed in the same
manner, the resulting MALDI-FTICR-MS images are shown in
Figures S12 and S13. A distinct feature of the rodent liver is
the synthesis of muricholic acids, that along with TCA are
major bile salts in rodent bile. These trihydroxy bile salt species
(and taurine-conjugated versions thereof) have an identical
molecular mass as cholic acid (and taurine-conjugated versions
thereof), and these isomeric species cannot be discriminated
using current IMS equipment. Hence, it is most likely that the
signal observed at m/z 514.28 corresponds to multiple taurine-
conjugated trihydroxy bile salts. The most abundant molecular
species observed in the connective tissue, parenchyma, and bile
duct of healthy dog and human liver were also observed in
healthy rat liver (Tables S2 and S3).
PCA was performed on the MALDI-FTICR-MSI data sets of
the healthy liver specimens in order to determine the
molecular proﬁles of each liver region in the animal species
studied.40 The top 10 of identiﬁed lipid classes were
determined for the positive and negative ion mode data sets
(Tables S2 and S3, respectively) and classiﬁed by the following
liver tissue structures: bile duct lumen, bile duct, connective
tissue, and parenchyma (Table 1). Localization of the most
abundant lipid species for each of these regions is also depicted
in Figures 1, 2, and 4. The same molecular classes were
observed in the examined structures across all species, the only
diﬀerence was the pattern of bile salt conjugation. In human
and mild PSC liver tissue, both glycine- and taurine-conjugated
bile salt species were detected, whereas only taurine-
conjugated bile salts were apparent in dog and rat liver.
Interestingly, in cases of severe PSC, taurine conjugated bile
salts, bilirubin (conjugated/unconjugated) and sulfated bile
salts/alcohols were present in the liver. Negative ion mode was
far more informative than positive ion mode, as the bile salts
and a wide range of lipids are more easily detected in negative
ion mode. In addition, the mass spectrum is less complicated as
only deprotonated ([M − H]−) species are present, whereas in
positive ion mode the spectrum is compounded by protonated
species ([M + H]+) and adducts of sodium ([M + Na]+) and
potassium ([M + K]+). The positive ion MALDI-FTICR-MS
images from healthy dog and human liver, as well as diseased
human liver are shown in Figures S4, S6, and S7 respectively.
In positive ion mode, a number of yet unknown molecular
species (ranging from m/z 544.24−592.24) separated by 16
Da were detected in the bile duct lumen (data not shown). No
speciﬁc molecular species were observed in the bile duct
epithelium in positive ion mode.
Table 1. Summary of Lipid Species Detected in Healthy and
Cholestatic Liver Tissuea
positive
sample bile duct bile duct lumen connective tissue parenchyma
rat NDb NAc PC and SM PC
dog NDb NAc PC and SM PC
human NDb NAc PC and SM PC
mild PSC NDb NAc PC and SM PC
severe PSC NDb NAc PC and SM PC
negative
sample bile duct
bile duct
lumen connective tissue parenchyma
rat ST and
ST−OH
BA (T) PA, PS, and SM PA, PE, and PI
dog ST and
ST−OH
BA (T) PA, PS, and SM PA, PE, and PI
human ST and
ST−OH
BA (G/T) PA, PS, and SM PA, PE, and PI
mild
PSC
ST and
ST−OH
BA (G/T) PA, PS, and SM PA, PE, and PI
severe
PSC
ST and
ST−OH
BA (G/T/
S)
and BIL
PA, PS, and SM PA, PE, and PI
aSpecies in positive ion mode were observed as protonated ([M +
H]+ molecule, sodium ([M + Na]+) and potassium ([M + K]+)
adducts. Species in negative ion mode were observed as deprotonated
([M − H]−). Key: bile acids (BA), bilirubin (BIL), phosphatidic acid
(PA), phosphatidylethanolamine (PE), phosphatidylserine (PS),
phosphatidylinositol (PI), phosphatidylcholine (PC), sphingomyelin
(SM), sulfatide (ST), and hydroxylated-sulfatide (ST−OH). Glycine
(G), taurine (T), and sulfate (S). bNo species related to the bile duct
were detected in the positive ion mode. cUnknown species present in
the bile duct lumen (identiﬁcation in progress).
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■ CONCLUSIONS
Using MALDI-MSI, we identiﬁed lipid-speciﬁc distributions in
diﬀerent compartments of the liver in all three species (rat,
dog, and human), in both positive and negative ion mode. In
the studied liver specimens, bile salts were largely conﬁned
within the biliary lumen. It will be interesting to examine the
spatial distribution of the distinct bile salt species in the setting
of bile salt retention as a consequence of intra- or extrahepatic
bile duct obstruction. (Hydroxylated)-sulfatides were identiﬁed
as speciﬁc molecular marker for the bile ducts and localized
uniquely to bile duct epithelium. Detection of 5-CS and
G(C)DCA-S allowed the discrimination between healthy
human liver and liver from patients with severe PSC, and
these molecules could potentially be used as diagnostic
markers. Experimental links with inﬂammatory events warrants
exploration of a possible involvement of sulfatides in
inﬂammatory cholangiopathies like PBC and PSC.
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Figure S1. Information on bile acids. (A) Base structure of bile
acids and (B) positions of the hydroxyl groups and site of
conjugation. (C) Observed masses of bile acid standards in
negative ion mode. Figure S2. MALDI-MS/MS spectra of
deprotonated ([M-H]−) bile acid standards in negative ion
mode. (A) cholic acid (m/z 407.26), (B) chenodeoxycholic
acid (m/z 391.27), (C) deoxycholic acid (m/z 391.27), (D)
lithocholic acid (m/z 375.27), (E) taurocholic acid (m/z
514.28), (F) glycocholic acid (m/z 464.30), (G) taurodeox-
ycholic acid (m/z 498.30), (H) glycodeoxycholic acid (m/z
448.30), (I) taurochenodeoxycholic acid (m/z 498.30), (J)
glycochenodeoxycholic acid (m/z 448.30). Figure S3:
MALDI-IMS-MS of isomeric bile acids in negative ion mode.
Mobilograms of (A) DCA/CDCA (m/z 391.27), (B) TDCA/
TCDCA (m/z 498.28) and (C) GDCA/GCDCA (m/z
448.30). Figure S4. Multimodal imaging of healthy dog liver
tissue. (I) Optical image of the tissue section prior to matrix
application. Positive-ion mode (A) MALDI-MS and (B)
MALDI-FTICR-MS images showing the distribution of
selected molecular species in the (II) bile duct lumen
(unknown at m/z 576.2418), (III) blood vessels (heme
[M]+ at m/z 616.1804), (IV) connective tissue ([PC
(32:0)+K]+ at m/z 772.5254), (V) parenchyma ([PC
(38:4)+K]+ at m/z 848.5564) and (VI) overlay of the selected
species. (Designated masses are from MALDI-FTICR-MS
imaging measurements, MALDI-MS image ﬁeld of view
141828 pixels, area 124 mm2 and spatial resolution 50 μm,
MALDI-FTICR-MS image ﬁeld of view 41700 pixels, 9.3 mm2
area and spatial resolution 15 μm. Both images normalized
with TIC). Figure S5. MALDI-MS/MS spectra obtained from
the most abundant species. MALDI-MS/MS spectra obtained
from (A) bile duct lumen, (B) connective tissue, (C)
parenchyma and (D) bile duct. Spectra obtained from healthy
dog liver tissue. Figure S6. Multimodal imaging of healthy
human liver tissue. (I) Optical image of tissue section prior to
matrix application. Positive-ion mode (A) MALDI-MS and (B)
MALDI-FTICR-MS images showing the distribution of
selected molecular species in the (II) bile duct lumen
(unknown at m/z 560.2427), (III) blood vessels (heme
[M]+ at m/z 616.1782), (IV) connective tissue ([PC
(32:0)+K]+ at m/z 772.5254), (V) parenchyma ([PC
(34:2)+K]+ at m/z 796.5252) and (VI) overlay of the selected
species. (Designated masses are from MALDI-FTICR-MS
imaging measurements, MALDI-MS image ﬁeld of view 72058
pixels, area 110 mm2 and spatial resolution 50 μm, MALDI-
FTICR-MS image ﬁeld of view 22338 pixels, 5 mm2 area and
spatial resolution 15 μm. Images normalized with TIC). Figure
S7. Multimodal imaging of liver from a patient with mild PSC
(case 1). (A) Optical image of tissue section prior to matrix
application. Positive-ion mode MALDI-FTICR-MS images
showing the distribution of selected molecular species in the
(B) bile duct lumen (unknown at m/z 560.2434), (C) heme
([M]+) at m/z 616.1804, (D) connective tissue ([PC
(32:0)+K]+ at m/z 772.5251), (E) parenchyma ([PC
(34:2)+K]+ at m/z 796.5254) and (F) overlay of the selected
species. (Designated masses are from MALDI-FTICR-MS
imaging measurements, ﬁeld of view 20238 pixels, area 10 mm2
and spatial resolution 15 μm. Images normalized with TIC).
Figure S8. MALDI-MS/MS spectra of 5-CS and GCDCA-S in
negative ion mode. (A) MALDI-MS/MS spectra of 5-CS at m/
z 531.28 obtained from severe PSC liver (blue) and whole-
body zebraﬁsh (red) tissue sections. (B) MALDI-MS/MS
spectra of G(C)DCA-S at m/z 528.24 obtained from pure
standard (blue) and severe PSC liver tissue section (red). *
indicate peaks coming from unidentiﬁed endogenous species
tentatively identiﬁed as fatty acids. Figure S9. Comparison of
immunohistochemical stain and MALDI-MS images from
initial patient with severe PSC (case 2). (A) Optical image of
tissue section prior to matrix application and (B) cytokeratin
staining of a consecutive tissue section. MALDI-MS images
showing the distribution of (C) [TCA-H]− at m/z 514.28, (D)
5-cyprinolsulfate ([M-H]−) at m/z 531.30, (E) heme ([M-
H]−) at m/z 615.17, (F) [PA (18:0_18:1)-H]− at m/z 701.51,
(G) [PI (18:0_20:4)-H]− at m/z 885.55, (H) [ST−OH
(18:1_24:0)-H]− at m/z 906.63 and (I) bilirubin diglucur-
onide ([M-H]−) at m/z 935.32. (J) Overlay of the selected
species. (Field of view 81186 pixels, area 8 mm2 and spatial
resolution 10 μm. Images normalized with TIC). Figure S10.
Multimodal imaging of liver tissue from patients with severe
PSC (cases 3−6). (A) Optical image of tissue section prior to
matrix application, (B) H&E staining of tissue sections post
imaging and (C) cytokeratin staining of a consecutive tissue
section. Negative-ion mode MALDI-FTICR-MS images
showing the distribution of (D) [TCDCA/TDCA-H]− at m/
z 498.2896, (E) [TCA-H]− at m/z 514.2844, (F) [G(C)-
DCAS-H]− at m/z 528.2639, (G) [5-CS-H]− at m/z 531.2998,
(H) [PS (18:0_18:1)-H]− at m/z 788.5449, (I) [PI
(18:0_18:2)-H]− at m/z 861.5502, (J) [ST−OH
(18:1_24:0)-H]− at m/z 906.6352 and (K) overlay of the
selected species. (PSC cases 3−6 ﬁelds of view 10356, 25482,
18987, and 21872 pixels and areas 2.3, 5.7, 4.2, and 4.8 mm2
respectively. Spatial resolution of all images 15 μm, normalized
with TIC). Figure S11. Receiver operating characteristic
(ROC) analysis of (A) G(C)DCA-S at m/z 528.2642 and (B)
5-CS at m/z 531.2999 from healthy liver tissue and tissue from
severe PSC cases. Inserts show the relative ion intensity of the
displayed ions. Figure S12. Multimodal imaging of healthy rat
liver tissue. (A) Optical image of tissue section prior to matrix
application. Negative-ion mode MALDI-FTICR-MS images
showing the distribution of selected molecular species in the
(B) bile duct lumen ([TCA-H]− at m/z 514.2845), (C)
connective tissue ([PA (18:0_18:1)-H]− at m/z 701.5129),
(D) parenchyma ([PI (18:0_20:4)-H]− at m/z 885.5499), (E)
bile duct ([ST−OH (18:1_24:0)-H]− at m/z 906.6348) and
(F) overlay of the selected species. (Designated masses are
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from MALDI-FTICR-MS imaging measurements, ﬁeld of view
4352 pixels, area 1 mm2 and spatial resolution 15 μm. Images
normalized with TIC). Figure S13. Multimodal imaging of
healthy rat liver tissue. (A) Optical image of tissue section
prior to matrix application. Positive-ion mode MALDI-FTICR-
MS images showing the distribution of selected molecular
species in the (B) bile duct lumen (unknown at m/z
560.2414), (C) heme ([M]+) at m/z 616.1775, (D)
connective tissue ([PC (32:0)+K]+ at m/z 772.5254), (E)
parenchyma ([PC (38:4)+K]+ at m/z 848.5566) and (F)
overlay of the selected species. (Designated masses are from
MALDI-FTICR-MS imaging measurements, ﬁeld of view 400
pixels, area 3.8 mm2 and spatial resolution 100 μm. Images
normalized with TIC). Table S1. Serum biochemistry from all
PSC patients in this study. Table S2. Comparison of lipids
present in the diﬀerent areas of the liver across diﬀerent species
in positive ion mode. Table S3. Comparison of lipids present
in the diﬀerent areas of the liver across diﬀerent species in
negative ion mode. Table S4. ROC values for other molecular
markers. The Supporting Information is available free of charge
on the ACS Publications website at DOI: 10.1021/
acs.analchem.8b01378.
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